ClinicalTrials.gg
RecruitingNCT07498231COMA-NETUpdated Apr 8, 2026

COronoary Microcirculation Analysis NETwork

An interventional study of Coronary microvascular function assessment and Coronary microvascular function assessment in Coronary Artery Disease, Microcirculation Resistance and Microcirculation; Biomarkers; Myocardial Ischemia, sponsored by Medical University of Bialystok. Recruiting at 1 site in Poland. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Medical University of Bialystok · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Oct 2025, registered Mar 2026).
  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 154 studies in Coronary Artery Disease with a site in Poland — 33 open to participants now, 47 under way, 4 of them phase 3. Coronary Artery Disease · Poland.

Planned enrollment
78th of 114
180 · median 348
Started
2025
with 10 others
No phase
64 of 154
17 open now
Primary completion
2027-10
later than 30 of 46 live
Registered
153rd of 154
by date
Lead sponsor
3 of 154
Medical University of Bialystok

Among the 154 studies in Coronary Artery Disease with a site in Poland, this one is the 78th largest by planned enrollment of the 114 interventional ones that give a count, is one of 11 that started in 2025, is one of 64 with no phase, reaches primary completion later than 30 of the 46 other live ones, and was the 153rd registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

33 of the 154 studies in Coronary Artery Disease with a site in Poland are open now. Recruiting first, the newest first:

27 more — sign in →

All 33 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 154 studies in Coronary Artery Disease with a site in Poland, or all of them as a file.
02

Study summary

COMA.NET (Coronary Microcirculation Analysis Network) is a prospective, randomized, open-label, parallel-group clinical trial designed to determine whether endotype-guided pharmacotherapy is superior to standard care in improving quality of life in patients with ischemia with non-obstructive coronary arteries. Approximately 180-190 participants with objective ischemia will be randomized to either the control or the intervention group.

Pharmacotherapy based on the endotype established during intracoronary assessment will be introduced in the intervention arm of the study. The primary endpoint is the change in the Seattle Angina Questionnaire (SAQ) score from baseline to 3 months. Secondary endpoints include the diagnostic accuracy of transthoracic echocardiographic coronary flow velocity reserve (CFVR), the incidence of adverse events, associations between biomarkers and coronary microvascular dysfunction (CMD), and the identification of risk factors for specific CMD endotypes.

Participants will undergo invasive functional evaluation of the coronary microcirculation, measurement of echocardiographic CFVR, and analysis of selected circulating biomarkers. The study cohort will be followed up at three and six months and will include reassessment of quality of life (Seattle Angina Questionnaire, EuroQol 5-Dimensions 5-Level questionnaire, 12-item Short Form Health Survey), anxiety (Generalized Anxiety Disorder-7 score), and functional status (6-minute walk test).

The study began in October 2025. Primary completion is anticipated in October 2027, and the overall study completion date is expected in March 2028.

Read the detailed description

According to the European Society of Cardiology (ESC) guidelines on chronic coronary syndromes, up to 70% of patients presenting with anginal symptoms and ischemia on non-invasive tests demonstrate no significant coronary artery disease on coronary angiography (INOCA - ischemia with non-obstructive coronary arteries). The underlying pathophysiology of this condition may include functional or structural abnormalities of the coronary microcirculation.

The aforementioned ESC guidelines recommend invasive coronary functional testing as a primary diagnostic strategy in persistently symptomatic patients with ischemia with non-obstructive coronary arteries (INOCA) or angina with non-obstructive coronary arteries (ANOCA) and impaired quality of life, despite medical treatment (Class I recommendation). Identification of the specific coronary microvascular dysfunction (CMD) endotype or epicardial vasospastic angina is crucial for the introduction of optimal, targeted pharmacological therapy. Therefore, this study addresses a critical evidence gap. As a superiority trial, it aims to determine whether endotype-guided pharmacotherapy is superior to standard care in improving quality of life and relieving symptoms over a 3-month period. The primary hypothesis is that endotype-guided therapy will result in a greater improvement in the Seattle Angina Questionnaire (SAQ) score compared with standard therapy at 3 months of follow-up.

COMA.NET (Coronary Microcirculation Analysis Network) is a prospective, randomized, open-label, interventional clinical trial with a parallel-group design. The eligible sample for this study consists of adults with chronic coronary syndrome, proven myocardial ischemia, and excluded obstructive coronary disease, either by invasive coronary angiography or coronary computed tomography angiography (CCTA) (defined as no significant epicardial coronary stenosis).

The sample size was calculated using a conservative approach comparing mean change scores between groups, with a two-sided alpha level of 0.05 and 80% statistical power. Under these assumptions, approximately 160 evaluable participants are required. We anticipate an attrition rate of 15% (including loss to follow-up and incomplete questionnaire data); thus, the total planned enrollment is approximately 180-190 participants.

Participants will be randomized in a 1:1 allocation ratio to one of two arms: the intervention group or the control group. Randomization will be performed using a simple randomization procedure based on a computer-generated randomization sequence with permuted blocks of variable size (4 and 6).

According to the study protocol, prior to hospital admission, all participants will be adequately prepared by discontinuing pharmacotherapy known to interfere with vasoreactivity (e.g., non-dihydropyridine calcium channel blockers such as verapamil and diltiazem), in accordance with appropriate washout periods.

On admission, blood and urine samples will be collected for analysis of redox and inflammatory biomarkers, including non-enzymatic antioxidants, enzymatic antioxidants, total antioxidant capacity and oxidative status, markers of oxidative damage, cytokines, chemokines, growth factors, damage-associated molecular patterns (DAMPs), and matrix metalloproteinases (MMPs 1-14) and their tissue inhibitors. All biomarker analyses will be performed using validated laboratory methods according to established protocols.

Overall quality of life (QoL) assessment will be performed using the Seattle Angina Questionnaire (SAQ), EuroQol 5-Dimensions 5-Level questionnaire (EQ-5D-5L), Generalized Anxiety Disorder-7 (GAD-7) score, 12-item Short Form Health Survey (SF-12), and Six-Minute Walk Test (6MWT) distance at baseline and follow-up.

All participants will undergo transthoracic echocardiography. Coronary flow velocity in the left anterior descending (LAD) artery will be assessed using pulsed-wave Doppler at rest and during regadenoson-induced hyperemia. Coronary flow velocity reserve (CFVR) will be calculated as the ratio of hyperemic to resting coronary flow velocity.

Subsequently, invasive diagnostics will be performed in both groups in two consecutive stages:

  1. Coronary vasomotor testing: Intracoronary bolus administration of acetylcholine in increasing concentrations during coronary angiography will be used to evaluate epicardial and microvascular vasomotor function.
  2. Microcirculatory function evaluation: Coronary flow reserve (CFR) and the index of microvascular resistance (IMR) will be assessed using the Coroventis CoroFlow™ Cardiovascular System, with hyperemia induced by intravenous regadenoson. CMD endotypes will be defined according to prespecified ESC criteria based on invasive coronary measurements.

Thereafter, following the examinations, patients will complete a numerical rating scale evaluating discomfort associated with the procedures.

In the intervention arm, antianginal treatment will be initiated in accordance with current ESC guidelines and tailored to specific CMD endotypes. The control group will receive standard pharmacotherapy according to current clinical practice, without endotype-specific treatment selection.

Participants initially assigned to the control group will cross over to the intervention arm at the 3-month follow-up. Following treatment revision according to the diagnosed endotype, both groups will be reassessed by telephone at 6 months from baseline using the previously described scales. Participants in the intervention arm will receive a follow-up telephone call one month after initiation of the intervention to assess clinical status, medication tolerance, adherence, and, if appropriate, to up-titrate prescribed medications.

At 3 months after the index hospitalization, participants in the intervention arm will undergo outpatient follow-up evaluation, including the SAQ, EQ-5D-5L, SF-12, 6-minute walk test, and GAD-7 score. Statistical analyses will be performed according to the intention-to-treat (ITT) and per-protocol principles.

The primary endpoint is the between-group difference in change in SAQ Summary Score at 3 months.

Secondary endpoints include:

  • Comparison of treatment strategies
  • Assessment of the diagnostic accuracy of echocardiographic CFVR
  • Incidence of adverse events
  • Associations between biomarkers and CMD
  • Identification of risk factors for specific CMD endotypes The study commenced in October 2025. Participants will be recruited for approximately 21 months. The primary completion date will occur when the last enrolled patient completes follow-up (estimated October 2027). The overall study completion date, defined as completion of all study-related procedures and follow-up, is expected in March 2028.

This trial is designed to provide comprehensive data regarding the epidemiology, pathophysiological endotypes, and biomarkers of coronary vasomotor disorders in patients with INOCA. Furthermore, it will evaluate the clinical utility of invasive and non-invasive diagnostic tests and assess the impact of endotype-based pharmacotherapy on patient-related outcomes. The findings may contribute to the refinement of diagnostic algorithms and patient-centered management strategies.

03

Conditions studied

  • Coronary Artery Disease
  • Microcirculation Resistance
  • Microcirculation; Biomarkers; Myocardial Ischemia
  • Microcirculatory Dysfunction
  • Microcirculatory Status
  • Echocardiography
  • Doppler Echocardiography

Keywords

  • coma.net
  • coma-net
  • coronary microcirculation
  • ANOCA
  • INOCA
  • angina with non-obstructive coronary arteries
  • ischemia with non-obstructive coronary arteries
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

a. Chronic coronary syndrome c. Anginal symptoms > CCS class I or angina equivalent d. Myocardial ischemia confirmed by non-invasive testing e. Provision of to participate in the study

Exclusion criteria

Exclusion Criteria:

  1. Angiographically significant coronary artery stenosis or FFR \< 0.8
  2. Renal insufficiency with \< 30 ml/min/1.73 m²
  3. \< 40%
  4. Hypertrophic cardiomyopathy
  5. Acute coronary syndrome within \< 90 days
  6. Percutaneous coronary intervention (PCI) within \< 90 days
  7. Previous coronary artery bypass grafting (CABG)
  8. Anemia \< 10 g/dL or thrombocytopenia \< 100,000/µL
  9. Intraventricular conduction disturbances preventing ST-T segment assessment
  10. Severe concomitant valvular heart disease
  11. Active
  12. Type 1 diabetes mellitus
  13. Coronary artery anatomical abnormalities precluding assessment using PressureWire X (myocardial bridge causing > 50% luminal narrowing of the investigated vessel, severe coronary tortuosity, inability to properly cannulate coronary ostia)
  14. Pregnancy
  15. Heart failure ≥ class III
  16. Asthma or with severe irreversible airflow obstruction
  17. Atrial fibrillation
  18. Second- or third-degree atrioventricular block without pacemaker implantation (IPG)
  19. Manifest pre-excitation on or history of AVRT episodes without prior ablation of the accessory pathway
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Endotype-Guided Treatment Group

    Participants undergo invasive and non-invasive assessment of coronary microvascular function to determine the INOCA endotype. The invasive assessment includes intracoronary acetylcholine provocation testing followed by guidewire-based measurement of coronary flow reserve and index of microvascular resistance during pharmacologically induced hyperemia. Non-invasive assessment includes echocardiographic coronary flow velocity reserve measurement in the left anterior descending artery. Based on the identified endotype of coronary microvascular dysfunction, participants receive guideline-directed pharmacotherapy targeted to the underlying mechanism in accordance with contemporary European Society of Cardiology recommendations. Follow-up assessments include quality-of-life questionnaires, functional capacity testing, and laboratory evaluation.

    Diagnostic Test: Coronary microvascular function assessment

  • Active comparator
    Standard Care Group

    Participants undergo the same invasive and non-invasive assessment of coronary microvascular function. Pharmacotherapy is determined by the treating physician according to standard clinical practice, without protocol-mandated endotype-guided treatment selection.

    Diagnostic Test: Coronary microvascular function assessment

Interventions

  • Diagnostic testCoronary microvascular function assessment

    Comprehensive invasive and non-invasive evaluation of coronary microvascular function used to determine microvascular dysfunction endotype and guide treatment selection.

    Also known as: Endotype-guided management

  • Diagnostic testCoronary microvascular function assessment

    Comprehensive invasive and non-invasive evaluation of coronary microvascular function used to determine microvascular dysfunction endotype without endotype-guided management.

    Also known as: Physician-guided standard care

06

What researchers measure

Primary outcomes

  1. Effectiveness of endotype-guided pharmacotherapy for coronary microvascular dysfunction

    Comparison of the effectiveness of targeted pharmacotherapy tailored to the specific endotype of coronary microvascular dysfunction versus standard guideline-based pharmacotherapy. Assessment of changes in angina-related health status over time between study groups using the Seattle Angina Questionnaire (SAQ) ranging from 0 to 100, with higher scores indicating better health status and less angina-related limitations.

    Time frame: Assessed at baseline and at 3 months follow-up

Secondary outcomes

  1. Prognostic value of selected blood and urinary biomarkers

    Assessment whether selected biochemical markers measured in blood and urine are associated with the presence and severity of coronary microvascular dysfunction and whether they provide incremental prognostic information.

    Time frame: 12 months

  2. EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L) index score

    Assessment of changes in health-related quality of life including mobility, self-care, usual activities, pain/discomfort and anxiety/depression, ranging from -0.590 to 1.000 (based on values set for Polish population), with higher scores value indicating better health status, evaluated before and after targeted pharmacotherapy.

    Time frame: Assessed at baseline, after 3 and 6 months

  3. Diagnostic value of echocardiographic coronary velocity flow reserve (CFVR) assessment

    Assessment of the diagnostic performance of echocardiographically measured coronary flow velocity reserve in detecting coronary microvascular dysfunction, compared with invasive coronary function testing as the reference standard.

    Time frame: 12 months

  4. 12-item Short Form health survey (SF-12) score

    Assessment of changes in health-related quality of life reflecting physical and mental health status, ranging from 0 to 100, with higher scores indicating better health status, evaluated before and after targeted pharmacotherapy.

    Time frame: Assessed at baseline, after 3 and 6 months

  5. Generalized Anxiety Disorder-7 (GAD-7) score

    Assessment of changes in anxiety severity, ranging from 0 to 21, with higher scores indicating greater anxiety severity, evaluated before and after targeted pharmacotherapy.

    Time frame: Assessed at baseline, after 3 and 6 months

  6. Six-Minute Walk Test (6MWT) distance

    Assessment of changes in functional exercise capacity over time before and after targeted pharmacotherapy.

    Time frame: Assessed at baseline and after 3 months

Other outcomes

  1. Risk factors for specific endotypes of coronary microvascular dysfunction

    To identify clinical, demographic, and biochemical factors associated with the occurrence of individual endotypes of coronary microvascular dysfunction.

    Time frame: 12 months

  2. Prevalence of coronary microvascular dysfunction endotypes in the Polish population

    Determination of the frequency of individual endotypes of coronary microvascular dysfunction in the studied Polish population and to describe their clinical characteristics.

    Time frame: 12 months

  3. Adverse events

    Assessment of the incidence and severity of adverse events occurring during the study period, including those related to diagnostic procedures and pharmacotherapy.

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
  • University Clinical Hospital, Department of Invasive Cardiology, Internal Medicine with CICU and Catheterization Laboratory-Uniwersytecki Szpital Kliniczny w Białymstoku, Klinika Kardiologii Inwazyjnej, Chorób Wewnętrznych z OIOK i Pracownią Hemodynamiki
    Bialystok, 15-276, Poland
    Recruiting
    • Maciej A. Poludniewski, MD, PhD · Contactmaciej.poludniewski@umb.edu.pl · +48 85 831 84 96
    • Emil J. Dąbrowski, MD, PhD · Contactemil.dabrowski@umb.edu.pl · +48 85 831 84 96
    • Maciej A. Południewski, MD, PhD · Principal investigator
    • Emil J. Dąbrowski, MD, PhD · Principal investigator
    • Piotr Pogorzelski, MD · Sub investigator
    • Michał Święczkowski, MD · Sub investigator
    • Michał Łuczaj, MD · Sub investigator
    • Maciejczyk, MD, PhD · Sub investigator
    • Marcin Kożuch, MD, PhD · Sub investigator
    • Oliwia Grunwald, MD · Sub investigator
    • Sławomir Dobrzycki, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2027, 24 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 24 months is below that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2026
First posted
Mar 27, 2026
StartActual
Oct 10, 2025
Primary completionEst.
Oct 2027
CompletionEst.
Mar 2028
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07498231
Lead sponsor
Medical University of Bialystok
Responsible party
Sponsor
First posted
Mar 27, 2026
Start date
Oct 10, 2025
Primary completion
Oct 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Apr 8, 2026

Study contacts

Maciej A. Poludniewski, MD, PhD
Contact
maciej.poludniewski@umb.edu.pl
+48 85-831-84-96
Emil J. Dąbrowski, MD, PhD
Contact
emil.dabrowski@umb.edu.pl
+48 85-831-84-96
Sławomir Dobrzycki, MD, PhD
principal investigator · Medical University of Bialystok
Maciej A. Południewski, MD, PhD
study chair · Medical University of Bialystok
Emil J. Dąbrowski, MD, PhD
study chair · Medical University of Białystok

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion